Dr. David Young
Chief Executive Officer
Replay available
Processa Pharmaceuticals, Inc. (PCSA) Q3 2022 Earnings Call
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) Q3 2022 earnings conference call, held 2022-11-08. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Jim Stanker
Chief Financial Officer
Francois Briwa
Analyst, Oppenheimer
Naz Rahman
Analyst, Maxim Group
Bruce Witten
Analyst
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Processa Pharmaceuticals, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.029 -- 00:00:05.512 Greetings and welcome to Processa Pharmaceuticals third quarter 2022 00:00:05.512 -- 00:00:10.755 earnings call and corporate update. At this time, all participants 00:00:10.755 -- 00:00:15.858 are in a listen-only mode. A question and answer session will follow the 00:00:15.858 -- 00:00:17.659 formal presentation. 00:00:17.659 -- 00:00:20.821 As a reminder, this call is being recorded. 00:00:20.821 -- 00:00:25.744 It is now my pleasure to introduce Jim Stanker, Chief Financial Officer. 00:00:25.744 -- 00:00:28.305 Thank you, sir. You may begin. 00:00:28.305 -- 00:00:32.587 Thank you and welcome to Procesa's third quarter 2022 00:00:32.587 -- 00:00:35.689 results and clinical update conference call. 00:00:35.689 -- 00:00:41.212 We are very pleased to have recently reported positive results from our ongoing phase 00:00:41.212 -- 00:00:44.153 1b trial for PCS6422 00:00:44.414 -- 00:00:49.617 in GI cancer and from our recently completed phase 2a trial for 00:00:49.617 -- 00:00:51.617 PCS12852 00:00:51.818 -- 00:00:53.759 in gastroparesis. 00:00:53.759 -- 00:00:57.489 Dr. Young will discuss these later during the call. 00:00:57.489 -- 00:01:01.452 Joining me on the call today are our Chief Executive Officer, Dr. 00:01:01.452 -- 00:01:05.655 David Young, and our Chief Operating Officer, Mike Floyd. 00:01:05.655 -- 00:01:09.946 Shortly before this call, we filed our September 30, 2022 00:01:10.458 -- 00:01:15.821 Form 10-Q, and this morning issued a press release containing preliminary 00:01:15.821 -- 00:01:18.642 results from our PCS-12-852 00:01:19.264 -- 00:01:24.347 gastroparesis trial. I want to remind everyone that a PowerPoint presentation 00:01:24.347 -- 00:01:27.489 will accompany Dr. Young's prepared remarks. 00:01:27.489 -- 00...